Celgene Corporation
Aug 17, 2016
Add to Briefcase

Olympic Swimmer and Author Dara Torres Teams Up With Celgene to Launch SHOW MORE OF YOU Psoriasis Campaign

New Campaign Aims to Inspire People With Psoriasis to Show More of Their True Selves

SUMMIT, N.J.--(BUSINESS WIRE)-- Twelve-time Olympic medalist, best-selling author, host of a cable sports TV show, and mom Dara Torres dives into a very important conversation this summer as she teams up with Celgene Corporation (NASDAQ:CELG) and Otezla® (apremilast) to launch the SHOW MORE OF YOU campaign. The campaign aims to inspire people living with psoriasis to raise awareness about their condition and celebrate their accomplishments. People with psoriasis and those who support them can join Torres and others at www.ShowMoreOfYou.com by sharing inspirational photos and messages of how they are showing more of their true selves.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160817005604/en/

Fresh off her poolside reporting assignment in Rio, Torres is speaking out about her personal experience with psoriasis. The Olympic swimmer and author was diagnosed with plaque psoriasis in the late 1990s. As one of 7.5 million people in the U.S. living with the disease, Torres knows what it means to overcome her fears and achieve her goals both in and out of the pool; she has not let the disease hold her back. In fact, she is the first and only female swimmer to represent the U.S. in five Olympic Games, and, at age 41, she was the oldest swimmer ever to earn a place on the U.S. team.

"I started noticing red, irritable, flaky patches on my elbows and back that seemed to be aggravated by stress, but I didn't let fear or embarrassment keep me out of a bathing suit or out of the pool," said Torres. "Instead, I worked with my dermatologist to manage my plaque psoriasis symptoms and didn't let the impact of the disease force me to adapt my life at the expense of my dreams. I want to encourage others to do the same."

People living with psoriasis often report that the disease has emotional and physical challenges. In fact, a survey reported nearly 9 out of 10 people living with psoriasis experienced self-consciousness or embarrassment about their condition. This survey also showed about half of patients with psoriasis are dissatisfied with their treatment options.

Otezla is a prescription medicine approved for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate. Please see Important Safety Information for Otezla below.

"My psoriasis patients not only deal with the physical symptoms of their disease, but because it is visible to the world, it can also affect how they see themselves and how they perceive others see them," said Jennifer C. Cather, MD, Modern Dermatology-Aesthetics Center in Dallas. "There are several options available to help manage the symptoms. Many people aren't aware that it's a systemic disease - meaning that it can affect the entire body. One option that treats plaque psoriasis differently is Otezla®. Otezla is a pill - not an injection, not a cream, and not a biologic. Patients should work with their dermatologist to determine a treatment option that best fits their needs."

"Celgene believes that people living with psoriasis should not only have different treatment options available, but should also have support to help them better understand their disease," said Scott Smith, President, Global Inflammation & Immunology, Celgene. "Through the SHOW MORE OF YOU campaign, we hope to help raise awareness of this chronic condition and celebrate the accomplishments people living with psoriasis achieve every day."

To learn more about the SHOW MORE OF YOU campaign, psoriasis, Torres' personal story, and to upload inspiring photos or messages, visit www.ShowMoreOfYou.com.

About Psoriasis

Psoriasis is a chronic skin condition affecting approximately 7.5 million people in the United States. The disease occurs when the immune system sends out faulty signals, which results in increased skin cell growth that may appear on the skin as raised, sometimes red patches covered with a silvery buildup of dead skin cells.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. For more information, please visit www.celgene.com. Follow Celgene on Social Media: @Celgene, Pinterest, LinkedIn, Facebook and YouTube.

About Otezla

Otezla® (apremilast) treats plaque psoriasis differently. Otezla is a pill - not an injection, not a cream, and not a biologic. For more information, talk to your dermatologist or visit www.otezla.com.


Otezla is a prescription medicine approved for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate.


You must not take Otezla if you are allergic to apremilast or to any of the ingredients in Otezla.

Otezla is associated with an increase in adverse reactions of depression. In clinical studies, some patients reported depression and suicidal behavior while taking Otezla. Some patients stopped taking Otezla due to depression. Before starting Otezla, tell your doctor if you have had feelings of depression, suicidal thoughts, or suicidal behavior. Be sure to tell your doctor if any of these symptoms or other mood changes develop or worsen during treatment with Otezla.

Some patients taking Otezla lost body weight. Your doctor should monitor your weight regularly. If unexplained or significant weight loss occurs, your doctor will decide if you should continue taking Otezla.

Some medicines may make Otezla® (apremilast) less effective, and should not be taken with Otezla. Tell your doctor about all the medicines you take, including prescription and nonprescription medicines.

Side effects of Otezla were diarrhea, nausea, upper respiratory tract infection, tension headache, and headache.

These are not all the possible side effects with Otezla. Ask your doctor about other potential side effects. Tell your doctor about any side effect that bothers you or does not go away.

Tell your doctor if you are pregnant, planning to become pregnant or planning to breastfeed. Otezla has not been studied in pregnant women or in women who are breastfeeding.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch, or call 1-800-332-1088.

Please click here for Full Prescribing Information.

Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. Celgene Corporation undertakes no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond Celgene's control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in Celgene's Annual Report on Form 10-K and other reports filed with the U.S. Securities and Exchange Commission.

© 2016 Celgene Corporation 07/16 USII-APR160173

For Celgene Corporation
Patrick E. Flanigan III, 908-673-9969
Corporate Vice President, Investor Relations
Catherine Cantone, 908-897-4256
Senior Director, Corporate Communications

Source: Celgene Corporation

News Provided by Acquire Media